When AMD steps up with its first-quarter results next week, it should be the chipmaker's strongest showing in a long time. Analysts see revenue rising 30% to $7.1 billion. It will be AMD's strongest year-over-year growth in nearly three years, and its fourth consecutive quarter of sharply accelerating revenue gains.

The news should be stronger on the bottom line. Those same Wall Street pros see a heartier 52% jump in earnings to $0.94 a share, almost as much as what AMD earned for all of last year. It will be a record showing for the company, and momentum is on its side. AMD has found a way to narrowly best analyst profit targets over the past year.

Image source: Getty Images.

But let's not call AMD a winner despite its improving fundamentals. Shares have plummeted 40% over the past year, and the company recently announced that it will be taking a charge of roughly $800 million for the banning of its MI308X processor in China. This charge is naturally not baked into financial update it will announce after the market close next Tuesday.

AMD's accelerating growth stems from the surging demand in AI chips and data center buildouts. Semiconductor stocks are notoriously cyclical, but this trend seems to have legs. The scenario would be rosier if AMD was thrust into the middle of a trade war, but the stock's discount appears to be Wood's opportunity. The shares are trading for a reasonable 22 times this year's estimates earnings and just 16 times next year's target. It's growing faster that pace now, so sustaining its healthy growth is the key to future upticks.

3. Intellia Therapeutics

Wood is a buyer of gene-editing stocks, and she's not the only one who sees a compelling price on Intellia Therapeutics these days. Andy Chen at Wolfe Research upgraded the stock to Outperform last week, believing that the developer of CRISPR-based therapies for treating devastating genetic orders is too low to ignore.

Despite a current market cap approaching $850 million, its strong net-cash position drops its enterprise value below $200 million. With brisk enrollment for the final clinical phase trial for a promising treatment, there is plenty of upside. Chen's $21 price target suggests that the stock will more than double from here.